Abstract
For the last one decade, scientists are working at developing nano anti-cancer drugs with the claim of ideal ones due to their targeted chemotherapic nature. These drugs have many beneficial properties such as targeted drug delivery and gene therapy modalities with minimum side effects. This article describes pros and cons and future perspectives of nano anti-cancer drugs. Efforts have been made to address the importance, special features, toxicities (general, blood identities, immune system and environmental) and future perspectives of nano anti-cancer drugs. It was concluded that nano anti-cancer drugs may be magic bullet drugs for cancer treatments leading to a bright future of the whole world.
Keywords: Nano anti-cancer drugs, pros and cons, toxicities, special features, future perspectives, immune system, micelles, dendrimers, micro-capsules, multidrug resistance, chemotherapy, paclitaxel, tumor, dendritic cells, neutropenia, thrombocytopenia, serum transaminase levels, gadolinium, fibrosis, synergistic efficacy, Deoxyribo nucleic acid, Interferon-, Inter Leukin-6, Inter Leukin-12, Multi drug resistance, Poly ethylene glycol, Red blood corpuscles, Small interfering ribo nucleic acids, Tumor necrosis factor, White blood corpuscles
Current Cancer Drug Targets
Title: Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Volume: 11 Issue: 2
Author(s): I. Ali
Affiliation:
Keywords: Nano anti-cancer drugs, pros and cons, toxicities, special features, future perspectives, immune system, micelles, dendrimers, micro-capsules, multidrug resistance, chemotherapy, paclitaxel, tumor, dendritic cells, neutropenia, thrombocytopenia, serum transaminase levels, gadolinium, fibrosis, synergistic efficacy, Deoxyribo nucleic acid, Interferon-, Inter Leukin-6, Inter Leukin-12, Multi drug resistance, Poly ethylene glycol, Red blood corpuscles, Small interfering ribo nucleic acids, Tumor necrosis factor, White blood corpuscles
Abstract: For the last one decade, scientists are working at developing nano anti-cancer drugs with the claim of ideal ones due to their targeted chemotherapic nature. These drugs have many beneficial properties such as targeted drug delivery and gene therapy modalities with minimum side effects. This article describes pros and cons and future perspectives of nano anti-cancer drugs. Efforts have been made to address the importance, special features, toxicities (general, blood identities, immune system and environmental) and future perspectives of nano anti-cancer drugs. It was concluded that nano anti-cancer drugs may be magic bullet drugs for cancer treatments leading to a bright future of the whole world.
Export Options
About this article
Cite this article as:
Ali I., Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives, Current Cancer Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/156800911794328457
DOI https://dx.doi.org/10.2174/156800911794328457 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Association of Fractalkine Receptor (T280M) Polymorphism in the Pathogenesis of Acute Coronary Syndrome in the Egyptian Population
Current Pharmaceutical Biotechnology Alterations in Plasma Triglyceride Concentrations Following Two Oral Meals with Different Fat Content in Patients with Type 2 Diabetes Mellitus
Current Vascular Pharmacology Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Role of Hydrogen Sulfide in Systemic and Pulmonary Hypertension: Cellular Mechanisms and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry HDL Therapy for the Treatment of Cardiovascular Diseases
Current Vascular Pharmacology Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Patients with Prehypertension - Do we have Enough Evidence to Treat them?
Current Vascular Pharmacology Editorial: Inflammation and Heart Diseases
Current Pharmaceutical Design Editorial (Heart Failure: The Need for Global Health Perspective)
Current Cardiology Reviews Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Editorial (Thematic Issue: Novel Insights into the Role of Anesthetics and Opioids in Organ or Tissue Protection)
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cardiology Reviews Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets Endothelial Function in Renal Transplant Recipients is Associated with Circulating Nitric Oxide, ACE Inhibitor Use and Time After Transplantation
Vascular Disease Prevention (Discontinued) Phenotyping and Genotyping of the Ryanodine Receptor-Associated Genetic Diseases Using Peripheral Lymphocytes
Current Pharmacogenomics Monitoring Cardiac Function During Idebenone Therapy in Friedreich's Ataxia
Current Pharmaceutical Design Therapeutic Approaches in the Stimulation of the Coronary Collateral Circulation
Current Cardiology Reviews Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets